Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Exclusive Story A Fresh IPO That Long-Term Investors Shouldn't IgnoreSubmitted by Jordan Chussler. First Published: 1/14/2026. 
At a Glance - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful of them can offer substantial short-term upside potential. Of course, IPOs carry significant downside risk. But even conservative investors shouldn't automatically dismiss recent listings, because some newly public companies may merit a place in buy-and-hold portfolios. While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn't touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies... Discover how to invest in the fund Trump uses to collect this income >> For one biotechnology company in the healthcare sector that just went public, that could precisely be the case. Last Year's IPO Success Stories Last year provides a clear example of why newly public companies shouldn't be written off by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have profited from its nearly 359% gain before the stock had been listed 30 days, but longer-term holders still enjoy strong returns. Others, such as Medline (NASDAQ: MDLN), refute the notion that all IPOs are risky startups. The medical products and services provider, which debuted publicly in December 2025, was founded in 1966 and already boasts a market cap in excess of $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—known for its packages of bacon—waited 89 years before going public. Since its January 2025 IPO, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44%, or $1 per share annually, making it an immediate consideration for income investors. After its IPO and with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for similar outcomes in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnostics and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals combine radioactive isotopes with a targeting module that seeks out particular cells (for example, cancer cells) to deliver localized doses of radiation, minimizing harm to healthy tissue that can be affected by conventional radiology treatments. According to industry consultancy Grand View Research, the global nuclear medicine market, estimated at nearly $18 billion in 2024, is forecast to reach almost $35 billion by 2030—a compound annual growth rate of about 10.16%. Importantly for Boston-based Aktis Oncology, Grand View Research notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States the predominant player. Aktis Oncology's Clinical-Stage Biotech Wall Street expects biotech IPO activity to rebound in 2026 after funding shifts in 2025 slowed listings from the healthcare sector. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and raised one of the largest sums for a biotech listing in recent memory. With $318 million in IPO proceeds, the firm now carries a market cap of about $3.34 billion. According to the company's prospectus, its executive team includes experts in drug development, regulatory approval, and commercialization, and management members have participated in bringing 14 currently FDA-approved products to market. Technically, Aktis develops targeted alpha radiopharmaceuticals: a class of precision cancer drugs that use proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not deter it from attracting the attention of Eli Lilly (NYSE: LLY), which anchored its IPO. According to Reuters, Eli Lilly purchased $100 million worth of AKTS shares as part of the offering. That investment builds on a partnership formed in 2024 to develop tumor-targeting radiopharmaceuticals; under that agreement, Aktis received $60 million in cash and an equity investment from Lilly, with potential milestone payments that could exceed $1 billion. The significance of Lilly's backing cannot be overstated. At about $1.01 trillion, Eli Lilly is the largest Big Pharma company by market cap, after the company's net income jumped nearly 109% year-over-year from 2023 to 2024. That trend may continue when Eli Lilly reports Q4 and full-year 2025 financials on Feb. 5. Between its earlier equity stake and the recent $100 million in AKTS shares purchased at the IPO, the maker of Zepbound now has a sizable financial interest in Aktis Oncology's success.
| 
